Authors: Salmon-Ceron, D Excler, JL Finkielsztein, L Autran, B Gluckman, JC Sicard, D Matthews, TJ Meignier, B Valentin, C El Habib, R Blondeau, C Raux, M Moog, C Tartaglia, J Chong, P Klein, M Milcamps, B Heshmati, F Plotkin, S

Citation: D. Salmon-ceron et al., Safety and immunogenicity of a live recombinant canarypox virus expressingHIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection, AIDS RES H, 15(7), 1999, pp. 633-645